Green Fresh Biotechnology (1084) Fundamentals 2026 — P/E 78.4x, Revenue Analysis | SniperIQ
Green Fresh Biotechnology (1084) is a HK-listed Consumer Defensive company in Agricultural Farm Products with a market capitalization of HK$599M, trading at HK$0.69 on the HKSE. This SniperIQ fundamentals page covers Green Fresh Biotechnology's valuation (P/E 78.4x, P/B 0.6x), profitability (net margin 0.7%), revenue (¥904M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Green Fresh Biotechnology's market cap?
Green Fresh Biotechnology (1084) has a market capitalization of approximately HK$599M, trading at HK$0.69 on the HKSE. Market cap moves with the live share price.
What is Green Fresh Biotechnology's P/E ratio?
Green Fresh Biotechnology's trailing twelve-month P/E ratio is 78.4x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Green Fresh Biotechnology?
Green Fresh Biotechnology runs a net profit margin of 0.7%, a gross margin of 18.5%, and an operating margin of 3.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Green Fresh Biotechnology generate?
Green Fresh Biotechnology reported revenue of ¥904M for fiscal year 2025, with net income of ¥7M and earnings per share (EPS) of 0.0076. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Green Fresh Biotechnology pay a dividend?
Green Fresh Biotechnology offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Green Fresh Biotechnology financially healthy?
Green Fresh Biotechnology carries a debt-to-equity ratio of 0.71x and a current ratio of 1.68x, with a market beta of -0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Green Fresh Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Green Fresh Biotechnology (1084) the key facts are: market cap HK$599M, P/E 78.4x, revenue ¥904M, 52-week range 0.57-0.79. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Green Fresh Biotechnology's full fundamentals live
Get Green Fresh Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.